Abstract
AbstractDepression and anxiety disorders are the first and sixth leading cause of disability worldwide according to latest reports from the World Health Organization. Despite their high prevalence and the significant disability resulted, there are limited advances in new drug development. On the other hand, the advent of genome-wide association studies (GWAS) has greatly improved our understanding of the genetic basis underlying psychiatric disorders.In this work we employed gene-set analyses of GWAS summary statistics for drug repositioning. We explored five related GWAS datasets, including two on major depressive disorder (MDD-PGC and MDD-CONVERGE, with the latter focusing on severe melancholic depression), one on anxiety disorders, and two on depressive symptoms and neuroticism in the population. We extracted gene-sets associated with each drug from DSigDB and examined their association with each GWAS phenotype. We also performed repositioning analyses on meta-analyzed GWAS data, integrating evidence from all related phenotypes.Importantly, we showed that the repositioning hits are generally enriched for known psychiatric medications or those considered in clinical trials, except for MDD-PGC. Enrichment was seen for antidepressants and anxiolytics but also for antipsychotics. We also revealed new candidates or drug classes for repositioning, some of which were supported by experimental or clinical studies. For example, the top repositioning hit using meta-analyzed p-values was fendiline, which was shown to produce antidepressant-like effects in mouse models by inhibition of acid sphingomyelinase and reducing ceramide levels. Taken together, our findings suggest that human genomic data such as GWAS are useful in guiding drug discoveries for depression and anxiety disorders.
Publisher
Cold Spring Harbor Laboratory
Reference102 articles.
1. World Health Organization. Depression and Other Common Mental Disorders Global Health Estimates. Available at http://apps.who.int/iris/bitstream/10665/254610/1/WHO-MSD-MER-2017.2-eng.pdf?ua=1. (2017).
2. Relationship of anxiety and depression
3. The overlap between anxiety, depression, and obsessive-compulsive disorder;Dialogues in Clinical Neuroscience,2015
4. Evaluation of Outcomes With Citalopram for Depression Using Measurement-Based Care in STAR*D: Implications for Clinical Practice
5. Treatment-resistant depression: therapeutic trends, challenges, and future directions;Patient Preference and Adherence,2012
Cited by
4 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献